<unk>  is an effective first-line treatment for infection by Blastocystis species and is indicated for the treatment of infection by Cryptosporidium parvum or Giardia lamblia in immunocompetent adults and children. It is also an effective treatment option for infections caused by other protozoa and helminths (e.g., Entamoeba histolytica, Hymenolepis nana, Ascaris lumbricoides, and Cyclospora cayetanensis). Chronic hepatitis B<unk>  alone has shown preliminary evidence of efficacy in the treatment of chronic hepatitis B over a one-year course of therapy.<unk>  500 mg twice daily resulted in a decrease in serum HBV DNA in all of 4 HBeAg-positive patients, with undetectable HBV DNA in 2 of 4 patients, loss of HBeAg in 3 patients, and loss of HBsAg in one patient. Seven of 8 HBeAg-negative patients treated with<unk>  500 mg twice daily had undetectable HBV DNA and 2 had loss of HBsAg. Additionally,<unk>  monotherapy in one case and<unk>  plus adefovir in another case resulted in undetectable HBV DNA, loss of HBeAg and loss of HBsAg. These preliminary studies showed a higher rate of HBsAg loss than any currently licensed therapy for chronic hepatitis B. The similar mechanism of action of interferon and<unk>  suggest that stand-alone<unk>  therapy or<unk>  in concert with nucleos(t)ide analogs have the potential to increase loss of HBsAg, which is the ultimate end-point of therapy. A formal phase 2 study is being planned for 2009. Chronic hepatitis C Romark initially decided to focus on the possibility of treating chronic hepatitis C with<unk> . The drug garnered interest from the hepatology community after three phase II clinical trials involving the treatment of hepatitis C with<unk>  produced positive results for treatment efficacy and similar tolerability to placebo without any signs of toxicity. A meta-analysis from 2014 concluded that the previous held trials were of low-quality and with held with a risk of bias. The authors concluded that more randomized trials with low risk of bias are needed to determine if<unk>  can be used as an effective treatment for chronic hepatitis C patients.
Nitazoxanide
Diloxanide
Secnidazole
Benznidazole
Fexinidazole
Tinidazole
Metronidazole
Oxytetracycline